Elevance Health, Inc. (ELV) Stock Analysis and Metrics

Sector: Healthcare Industry: Healthcare Plans CIK: 0001156039

ROIC (Qtr) 0.02

Total Debt (Qtr) 30.95 Bn

Revenue Growth (1y) (Qtr) 8.51

Add ratio to table...

About

Elevance Health, Inc., known by its ticker symbol ELV, is a prominent player in the healthcare industry, dedicated to elevating and advancing the health of individuals and communities. The company operates through various segments, including Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It provides a wide range of health plans and services to diverse groups such as Individual, Employer Group, Medicare, Medicaid, and FEHB program members. Elevance Health's business model is multi-faceted, generating revenue from various sources....

Elevance Health, Inc., known by its ticker symbol ELV, is a prominent player in the healthcare industry, dedicated to elevating and advancing the health of individuals and communities. The company operates through various segments, including Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It provides a wide range of health plans and services to diverse groups such as Individual, Employer Group, Medicare, Medicaid, and FEHB program members.

Elevance Health's business model is multi-faceted, generating revenue from various sources. The Health Benefits segment offers a comprehensive suite of health plans and services, while CarelonRx segment deals with the pharmacy business, offering pharmacy services and pharmacy benefit management (PBM) services. Carelon Services integrates physical, behavioral, social, and pharmacy services to deliver affordable whole health, and the Corporate & Other segment manages other corporate functions.

The company's competitive edge lies in its broad network of providers, its ability to offer a wide range of products and services, and its strong brand recognition. Key competitors include other large health insurance companies such as UnitedHealth Group and CVS Health. Elevance Health's offerings cater to various customer needs, including individuals, employers, and government programs, delivered through channels like its own sales force, brokers, agents, and online platforms.

Elevance Health's financial performance hinges on its ability to accurately predict and effectively manage healthcare costs, grow membership, and revenue. External factors like changes in healthcare policy and regulations, as well as economic conditions, also impact its performance. The company's product pricing is based on current healthcare claim costs, emerging healthcare cost trends, administrative expenses, risk, and profit. Regular reviews of product designs and pricing guidelines ensure competitiveness and alignment with profitability goals and strategies.

The company's networks and provider relations are guided by local, regional, and national standards for network development, reimbursement, and contract methodologies. Market-based hospital reimbursement payments are established to be fair but competitive, and timely payments are ensured for physicians in the network.

Elevance Health's product and service brand names include CarelonRx, which deals with the pharmacy business, and Carelon Services, which integrates various health services. These brands, along with the company's main business activities, contribute to its strong position in the healthcare industry.

The company's operations are characterized by a seasonality in the Health Benefits segment, with benefit costs typically increasing during the year as risk-based members pay their contractual portion of claims responsibility under annual deductibles and reach their out-of-pocket maximum limits. Medical management activities are broad, facilitating improvements in the quality of care, promoting cost-effective medical care, and advancing health equity.

Investment thesis

Bull case

Elevance’s deliberate portfolio realignment—shifting from low‑margin Medicaid to higher‑margin Medicare Advantage and national employer accounts—creates a clear path for margin expansion. The company’s exit from underperforming geographies and its focus on high‑value D‑SNP products are expected to drive a 2% improvement in Medicare Advantage margins in 2026, a significant upside relative to current industry averages. By anchoring its strategy around disciplined pricing and a more favorable mix of members, the firm is positioning itself to capture incremental premium yields even as the overall medical loss ratio remains near 90%, thereby preserving revenue growth while trimming cost pressure. This disciplined approach should translate into a healthier earnings base, setting the stage for the projected 12% adjusted EPS growth in 2027 that management confidently outlines.
The Carillon platform is exhibiting robust organic growth, with Rx revenue up 20% YoY and Services up 57% YoY, underscoring the value of its risk‑based solutions in managing high‑cost care. Even as health‑plan membership declines, external clients are migrating to Carillon’s risk‑based contracts, which offer predictable cost controls and shared‑risk incentives that can offset the impact of reduced plan enrollment. The acquisition of CareBridge and the expansion into oncology and behavioral health further diversify Carillon’s revenue mix and lock in high‑margin specialty drug management. Because Carillon’s services generate a sizable fee‑for‑service component, the platform adds an additional, more resilient revenue stream that is less sensitive to policy‑driven enrollment swings, reinforcing the long‑term earnings power the company cites.
Elevance’s HealthOS platform, which is targeting 80% real‑time prior‑authorization and seamless data exchange across the provider network, represents a strategic technology advantage that can reduce administrative costs and improve member experience. By integrating advanced analytics and AI‑driven care coordination, the firm can identify cost‑savings opportunities early, thereby tightening benefit expense trends in a sector where medical costs are rising. These efficiencies are scalable across both health‑benefit and Carillon segments, amplifying margin gains while preserving service quality. The continued investment in HealthOS signals a commitment to a differentiated “Whole Health” model that can capture value in a crowded market, giving Elevance a sustainable competitive edge.
Recent policy developments—such as the One Big Beautiful Bill Act and the Inflation Reduction Act—offer a structural opportunity for Elevance to renegotiate Medicaid rates and align reimbursement with current utilization patterns. The company’s proactive engagement with state partners to refine program design and eligibility could yield higher rates and reduce the lag between experience and payment, directly improving Medicaid operating margins. Although the company forecasts a trough in Medicaid in 2026, the strategic dialogue with state regulators positions it to convert policy shifts into tangible revenue gains, thereby offsetting the short‑term volatility in that segment. This policy leverage aligns with Elevance’s broader vision of sustainable earnings and supports its long‑term margin targets.
Elevance’s capital deployment strategy—combining a $2.3 billion share‑repurchase program, a steady dividend, and targeted acquisitions—underscores a strong balance‑sheet posture that can absorb short‑term cost pressures while funding growth initiatives. The firm’s operating cash flow, projected to exceed $5.5 billion in 2026, provides ample liquidity to support both defensive measures (e.g., cost‑control investments) and offensive opportunities (e.g., expanding Carillon’s footprint or entering new markets). This financial flexibility mitigates the risk of capital constraints that could otherwise impede the execution of its multi‑segment strategy, reinforcing confidence in its ability to maintain a disciplined earnings trajectory.

Elevance’s deliberate portfolio realignment—shifting from low‑margin Medicaid to higher‑margin Medicare Advantage and national employer accounts—creates a clear path for margin expansion. The company’s exit from underperforming geographies and its focus on high‑value D‑SNP products are expected to drive a 2% improvement in Medicare Advantage margins in 2026, a significant upside relative to current industry averages. By anchoring its strategy around disciplined pricing and a more favorable mix of members, the firm is positioning itself to capture incremental premium yields even as the overall medical loss ratio remains near 90%, thereby preserving revenue growth while trimming cost pressure. This disciplined approach should translate into a healthier earnings base, setting the stage for the projected 12% adjusted EPS growth in 2027 that management confidently outlines.
The Carillon platform is exhibiting robust organic growth, with Rx revenue up 20% YoY and Services up 57% YoY, underscoring the value of its risk‑based solutions in managing high‑cost care. Even as health‑plan membership declines, external clients are migrating to Carillon’s risk‑based contracts, which offer predictable cost controls and shared‑risk incentives that can offset the impact of reduced plan enrollment. The acquisition of CareBridge and the expansion into oncology and behavioral health further diversify Carillon’s revenue mix and lock in high‑margin specialty drug management. Because Carillon’s services generate a sizable fee‑for‑service component, the platform adds an additional, more resilient revenue stream that is less sensitive to policy‑driven enrollment swings, reinforcing the long‑term earnings power the company cites.
Elevance’s HealthOS platform, which is targeting 80% real‑time prior‑authorization and seamless data exchange across the provider network, represents a strategic technology advantage that can reduce administrative costs and improve member experience. By integrating advanced analytics and AI‑driven care coordination, the firm can identify cost‑savings opportunities early, thereby tightening benefit expense trends in a sector where medical costs are rising. These efficiencies are scalable across both health‑benefit and Carillon segments, amplifying margin gains while preserving service quality. The continued investment in HealthOS signals a commitment to a differentiated “Whole Health” model that can capture value in a crowded market, giving Elevance a sustainable competitive edge.
Recent policy developments—such as the One Big Beautiful Bill Act and the Inflation Reduction Act—offer a structural opportunity for Elevance to renegotiate Medicaid rates and align reimbursement with current utilization patterns. The company’s proactive engagement with state partners to refine program design and eligibility could yield higher rates and reduce the lag between experience and payment, directly improving Medicaid operating margins. Although the company forecasts a trough in Medicaid in 2026, the strategic dialogue with state regulators positions it to convert policy shifts into tangible revenue gains, thereby offsetting the short‑term volatility in that segment. This policy leverage aligns with Elevance’s broader vision of sustainable earnings and supports its long‑term margin targets.
Elevance’s capital deployment strategy—combining a $2.3 billion share‑repurchase program, a steady dividend, and targeted acquisitions—underscores a strong balance‑sheet posture that can absorb short‑term cost pressures while funding growth initiatives. The firm’s operating cash flow, projected to exceed $5.5 billion in 2026, provides ample liquidity to support both defensive measures (e.g., cost‑control investments) and offensive opportunities (e.g., expanding Carillon’s footprint or entering new markets). This financial flexibility mitigates the risk of capital constraints that could otherwise impede the execution of its multi‑segment strategy, reinforcing confidence in its ability to maintain a disciplined earnings trajectory.

Bear case

Medicaid remains a structural drag on Elevance’s profitability, with the company projecting a negative 1.75% operating margin in 2026 and anticipating a 9–10% decline in enrollment. The ongoing reverification of eligibility and stricter state‑level requirements are likely to further erode rates, making it increasingly difficult to align payment with the high utilization of substance‑use disorder and behavioral‑health services that the company acknowledges as a persistent cost driver. Even with aggressive cost‑control initiatives, the margin compression could intensify if state budgets continue to tighten, potentially leading to a prolonged period of negative margin that will weigh on earnings.
The Medicare Advantage business, while offering a 2% margin improvement target, remains exposed to a lagging rate structure that fails to keep pace with rising medical costs, especially after the recent rate notice that indicated only a 0.09% increase. With the program’s cost trend projected to remain in the mid‑single‑digit range, any further delay or reduction in payment increases will compress margins and could undermine the company’s assumption of sustained earnings growth. Moreover, the complex risk‑adjustment framework and potential policy changes add an element of uncertainty that may jeopardize the projected profitability gains.
The expiration of enhanced subsidies in the ACA market will exacerbate the cost trend, as the company already projects a high‑single‑digit decline in membership and a sicker risk pool. A larger-than‑expected attrition could push the medical loss ratio higher and squeeze premiums, challenging the firm’s ability to maintain its current benefit expense ratio of 90.2% +/- 50 basis points. If the ACA market deteriorates further, the resulting downward pressure on revenue will force the company to tighten pricing even more aggressively, potentially eroding margins and diluting the expected 12% EPS growth trajectory.
CarillonRx faces significant revenue headwinds from declining health‑plan membership, which directly impacts pharmacy revenue. The company’s reliance on risk‑based contracts and external client expansion to offset this decline introduces uncertainty, as these arrangements may not fully compensate for the loss in volume. Additionally, any failure to control pharmacy cost growth—particularly in specialty drugs—could compress the mid‑single‑digit margin target that CarillonRx has set, eroding overall earnings power across the diversified platform.
Elevance’s execution risk is elevated by its aggressive portfolio restructuring and pricing discipline initiatives. Mispricing or misalignment of rates with the actual cost experience—especially in Medicaid—could result in unanticipated losses and erode investor confidence. The company’s heavy dependence on policy changes and state negotiations introduces a strategic vulnerability; any slowdown in state or federal program reforms could delay rate improvements and extend the period of negative margin, undermining the projected earnings base.

Medicaid remains a structural drag on Elevance’s profitability, with the company projecting a negative 1.75% operating margin in 2026 and anticipating a 9–10% decline in enrollment. The ongoing reverification of eligibility and stricter state‑level requirements are likely to further erode rates, making it increasingly difficult to align payment with the high utilization of substance‑use disorder and behavioral‑health services that the company acknowledges as a persistent cost driver. Even with aggressive cost‑control initiatives, the margin compression could intensify if state budgets continue to tighten, potentially leading to a prolonged period of negative margin that will weigh on earnings.
The Medicare Advantage business, while offering a 2% margin improvement target, remains exposed to a lagging rate structure that fails to keep pace with rising medical costs, especially after the recent rate notice that indicated only a 0.09% increase. With the program’s cost trend projected to remain in the mid‑single‑digit range, any further delay or reduction in payment increases will compress margins and could undermine the company’s assumption of sustained earnings growth. Moreover, the complex risk‑adjustment framework and potential policy changes add an element of uncertainty that may jeopardize the projected profitability gains.
The expiration of enhanced subsidies in the ACA market will exacerbate the cost trend, as the company already projects a high‑single‑digit decline in membership and a sicker risk pool. A larger-than‑expected attrition could push the medical loss ratio higher and squeeze premiums, challenging the firm’s ability to maintain its current benefit expense ratio of 90.2% +/- 50 basis points. If the ACA market deteriorates further, the resulting downward pressure on revenue will force the company to tighten pricing even more aggressively, potentially eroding margins and diluting the expected 12% EPS growth trajectory.
CarillonRx faces significant revenue headwinds from declining health‑plan membership, which directly impacts pharmacy revenue. The company’s reliance on risk‑based contracts and external client expansion to offset this decline introduces uncertainty, as these arrangements may not fully compensate for the loss in volume. Additionally, any failure to control pharmacy cost growth—particularly in specialty drugs—could compress the mid‑single‑digit margin target that CarillonRx has set, eroding overall earnings power across the diversified platform.
Elevance’s execution risk is elevated by its aggressive portfolio restructuring and pricing discipline initiatives. Mispricing or misalignment of rates with the actual cost experience—especially in Medicaid—could result in unanticipated losses and erode investor confidence. The company’s heavy dependence on policy changes and state negotiations introduces a strategic vulnerability; any slowdown in state or federal program reforms could delay rate improvements and extend the period of negative margin, undermining the projected earnings base.

Consolidated Entities Breakdown of Revenue (2025)

Investment Type Breakdown of Revenue (2025)

Peer comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CI	Cigna Group	-	-	-	31.46 Bn
2	MOH	Molina Healthcare, Inc.	-	-	-	3.77 Bn
3	ELV	Elevance Health, Inc.	-	-	-	30.95 Bn
4	PGNY	Progyny, Inc.	-	-	-	-
5	UNH	Unitedhealth Group Inc	-	-	-	78.39 Bn
6	HUM	Humana Inc	-	-	-	12.37 Bn
7	PFHO	Pacific Health Care Organization Inc	-	-	-	-
8	CNC	Centene Corp	-	-	-	17.40 Bn

Research Tools

Elevance Health, Inc. (NYSE: ELV)

About

Investment thesis

Bull case

Bear case

Consolidated Entities Breakdown of Revenue (2025)

Investment Type Breakdown of Revenue (2025)

Peer comparison

Research Tools

Elevance Health, Inc. (NYSE: ELV)

About

Investment thesis

Bull case

Bear case

Consolidated Entities Breakdown of Revenue (2025)

Investment Type Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password